Shots:
Slingshot AI has launched Ash, a personalized mental health support app, which is now available on both iOS & Android platforms
Slingshot AI also secured a Series A extension funding co-led by Radical & Forerunner Ventures, joined by existing investors a16z, Felicis, & Menlo, bringing its total capital raised to $93M
Ash is powered…
Shots:
Recently, the CHMP of the EMA adopted a positive opinion for Astellas’ Padcev + Keytruda combination therapy as the first-line treatment of patients with unresectable or metastatic urothelial cancer
Today, in an exclusive coverage, we bring an enlightening conversation with Ahsan Arozullah from Astellas Pharma, sharing insights from the P-III EV-302 study
Astellas looks…
Nicotine addiction is incredibly common, and more often than not, it is because many people haven’t found an effective way to quit smoking, vaping, or nicotine. Here are a few treatments you can use, as well as a few tips for lowering your nicotine intake.
Nicotine Replacement Therapy
Firstly, whether you are a smoker or…
Mental health disorders affect millions of people worldwide, yet only a fraction receive the treatment they need. This gap in care is often due to the complexities of mental health disorders and the challenge of finding the right treatment approach. Holistic mental health care, which combines medication and therapy, offers a comprehensive solution to this…
Shots:
In a stimulating conversation with PharmaShots, Dr. Susan Pandya shares insights from their presentation at SNO 2023 to strengthen Servier’s Neuro-Oncology Profile
While highlighting the details of vorasidenib, Susan articulately explains the study design of the P-III Indigo trial evaluating vorasidenib in patients with IDH-mutant diffuse glioma
With a fast-track designation and breakthrough therapy…
Shots:
With diverse applications in diagnostic imaging, theragnostics, and targeted therapy, radiopharmaceuticals are gradually tapping into an ocean of unlimited opportunities
By 2030, the radiopharmaceutical market size is expected to grow to $12.18B. In 2023, POINT Biopharma topped the list among radiopharma companies with a market cap of $726.88B followed by Novartis with a market…
Shots:
Dr. Lotus Mallbris shares the positive endpoint results of the VIVID-1 P-III study, evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease
While shedding light on the mechanism of mirkizumab, Lotus highlights that available therapies to treat Crohn’s disease often fail to achieve clinical…
Shots:
The US FDA approved 5 NDAs and 2 BLA in July 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 76 novel products in 2023
In July 2023, the major highlights drugs were Beyfortus (nirsevimab) approval for the prevention of RSV lower respiratory tract disease in…

